ARTV Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
32.0M
+18.8%
26.9M
+10.1%
24.4M
+11.4%
21.9M
-4.2%
22.9M
R&D
26.0M
+18.5%
21.9M
+13.5%
19.3M
+13.6%
17.0M
-3.6%
17.6M
SG&A
6.0M
+20.1%
5.0M
-3.0%
5.1M
+3.6%
4.9M
-6.2%
5.3M
Operating Income
-31954000
-18.8%
-26890000
-10.1%
-24430000
-11.4%
-21932000
+4.2%
-22897000
EBITDA
-31200000
-19.1%
-26198000
-10.2%
-23764000
-11.7%
-21266000
+4.4%
-22235000
Net Income
-28822000
-15.3%
-25005000
-6.3%
-23516000
-13.2%
-20772000
+3.5%
-21528000
EPS (Basic)
$-0.56
+11.1%
$-0.63
+33.7%
$-0.95
-11.8%
$-0.85
+3.4%
$-0.88
EPS (Diluted)
$-0.56
+11.1%
$-0.63
+33.7%
$-0.95
-11.8%
$-0.85
+3.4%
$-0.88
Shares (Diluted)
51.2M
+29.9%
39.4M
+59.7%
24.7M
+0.4%
24.6M
+0.4%
24.5M
Artiva Biotherapeutics (ARTV) — Financials